The basis for HIV immunotherapeutic vaccines

Vaccine

Volumn 20, Issue 5-6, 2001, Pages 688-705

  Peters, B S ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

HIV; Immunotherapeutics; Vaccines

Indexed keywords

ANTIGEN P24; BETA CHEMOKINE; CB4 P VACCINE; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DNA VACCINE; ENFUVIRTIDE; FP 21399; GAG PROTEIN; GLYCOPROTEIN GP 120; HEAT SHOCK PROTEIN 70; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEF PROTEIN; NYVAC VACCINE; P24 VLP VACCINE; POL PROTEIN; PROTEIN P17; RANTES; RECOMBINANT GLYCOPROTEIN GP 120; TENOFOVIR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VCP 1452; VCP 205; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; VIRUS VECTOR; ZIDOVUDINE; ZINTEVIR;

ALLOIMMUNIZATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; INFECTION CONTROL; LYMPHOCYTE COUNT; LYMPHOCYTOTOXICITY; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINIA VIRUS; VIRUS LOAD; VIRUS RECOMBINANT; VIRUS TRANSMISSION;

AIDS VACCINES; GENE PRODUCTS, TAT; GENETIC VECTORS; HIV; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; ISOANTIGENS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 0035852305     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00394-2     Document Type: Review

References (154)

1. HTLV-III - Neutralizing antibodies in patients with AIDS and AIDS-related complex
2. Kinetics of Gag-specific cytotoxic T-lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
3. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
4. High levels of anti-HIV-1 memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors
5. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T-lymphocytes
6. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine
7. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
8. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene
9. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
10. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques
11. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
12. Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1
13. Immunologic and virologic status after 14-18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort
14. Phenotypic analysis of human immunodeficiency virus (type 1) cell-medicated immune response after treatment with an HIV-1 immunogen
15. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant
16. Enhancement of HIV type 1 antigen-specific CD4+ T-cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen
17. CXCR4 and CCR5 expression on CD4+ T-cells in vivo and HIV-1 antigen beta-chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE)
18. Highly active antiretroviral therapy normalizes the potential for MIP-1-alpha production in HIV infection
19. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of >300
20. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomised, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs
21. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA
22. Induction of specific T-cell responses in HIV infection
23. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with human immunodeficiency virus infection
24. Immunization of HIV-infected patients with rgp160: Modulation of anti-rgp120 antibody spectrotype
25. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp 160 vaccine
26. Improved cell-medicated immune responses in HIV-1-infected asymptomatic individulas after immunization with envelope glycoprotein gp160
27. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
28. An HIV envelope protein vaccine induces CD4+ human cytolytic T-cells active against HIV-infected cells
29. The safety and immunogenicity of a human immunodeficiency virus type I (HIV) recombinant gp160 candidate vaccine in humans
30. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: Evaluation of the T-cell proliferative response
31. Active immunization of patients with HIV infection: A study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency
32. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults
33. Recombinant gp160 as a therapeutic vaccine for HIV-infection: Results of a large randomized, controlled trial
34. Results of a phase II double-blinded, multicenter, placebo-controlled HIV therapeutic vaccine trial
35. Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial
36. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients
37. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects
38. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic patients
39. Therapeutic vaccination (p24 VLP) of patients with advanced HIV-1 infection does not alter CD4 decline
40. Immunisation with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons
41. Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection
42. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T-lymphocyte reactivities in uninfected volunteers
43. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV, vCP2050) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
44. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in healthy volunteers
45. Safety and immunogenicity study on vCP1542/gp160 vaccine in patients treated with HAART for over 2 years
46. Discontinuation of HAART after a course of therapeutic vaccination with ALVAC1452 and rgp160 may be associated with delayed viral rebound kinetics
47. Association of HLA class I alleles with cytotoxic T-lymphocyte (CTL) responses to gag and env in recipients of ALVAC-HIV canarypox vaccines
48. Dendritic cells infected with recombinant canarypox virus induce potent anti-HIV cytolytic and helper T-cell responses from chronically infected individuals
49. Human immunodeficiency virus type 1 envelope-specific cytotoxic T-lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions
50. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120
51. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure
52. CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: Potential role in vaccine efficacy
53. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
54. Immune control of HIV-1 after early treatment of acute infection
55. Control of SIV rebound through structured treatment interruptions during early infection
56. A therapeutic HIV vaccine using coxsackie-HIV recombinants: A possible new strategy
57. Recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques
58. Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma
59. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen
60. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of pre-existing immunity to the vector
61. HIV infection and pathogenesis: What about chemokines?
62. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review
63. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains
64. Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T-cells
65. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1
66. Interferon alpha and Tat involvement in the immunosuppression of uninfected T-cells and CC-chemokine decline in AIDS
67. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge
68. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients
69. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
70. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 Tat vaccine
71. Human immunodeficiency virus tat gene transfer to the murine central nervous system using a replication-defective herpes simplex virus vector stimulates transforming growth factor beta 1 gene expression
72. The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice
73. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice
74. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid
75. Genetic immunization is a simple method for eliciting an immune response
76. Heterologous protection against influenza by injection of DNA encoding a viral protein
77. Nucleic acid-based immunisation against HIV-1; induction of protective in vivo immune responses
78. DNA inoculation induces cross clade anti-HIV-1 responses
79. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization
80. DNA vaccination as anti-HIV immunotherapy in infected chimpanzees
81. An anti-HIV strategy combining chemotherapy and therapeutic vaccination
82. Cellular cytotoxic response induced by DNA vaccination in HIV-infected patients
83. Enhancement of cellular immune response in HIV-1 seropositive individuals. A DNA-based trial
84. Immune responses in asymptomatic HIV-1 infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
85. Humoral and cellular immune responses to HIV-1 nef in mice DNA-immunised with non-replicating or self-replicating expression vectors
86. Macrophage inflammatory protein-1-alpha (MIP-1-alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1
87. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles
88. Immunogenicity of a novel DNA vaccine cassette expressing multiple human immunodeficiency virus (HIV-1) accessory genes
89. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
90. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids
91. Anti-major histocompatibility complex antibody responses in macaques via intradermal DNA immunizations
92. Cationic microparticles: A potent delivery system for DNA vaccines
93. Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-γ, IL-12, or IL-18 gene adjuvants
94. Immunization against SIVmne in macaques using multigenic DNA vaccines
95. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses
96. Detection of three distinct patterns of T-helper cell dysfunction in asymtomatic, human immunodeficiency virus seropositive patients. Independence of CD4+ cell numbers and clinical staging
97. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission
98. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines
99. Acquisition of host cell-surface-derived molecules by HIV-1
100. Common epitope in HIV-1 gp41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV-infected individuals
101. Does the HIV envelope induce a chronic graft-versus-host-like disease?
102. Anti-cell antibody in macaques
103. The ability of certain SIV vaccines to provoke reactions against normal cells
104. Allo-immunization elicits CD8+ T-cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women
105. Alloantigen-stimulated anti-HIV activity
106. Circumvention of defective CD4 T-helper cell function in HIV-infected individuals by stimulation with HLA alloantigens
107. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T-cell response from a type 2 to a type 1 cytokine profile
108. Immune response in human melanoma after transfer of an allogeneic class 1 major histocompatibility complex gene with DNA-liposome complexes
109. Semiallogeneic cell hybrids as therapeutic vaccines for cancer
110. Alloimmunization as a strategy for vaccine design against HIV/AIDS
111. Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates
112. Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity
113. Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection
114. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques
115. Gamma delta T-cells regulate mucosally induced tolerance in a dose-dependent fashion
116. Mechanisms of MHC class I-restricted antigen processing
117. Anthrax protective antigen forms oligomers during intoxication of mammalian cells
118. Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin
119. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo
120. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
121. A randomised trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection
122. -1 CD4 T-cells and undetectable viral load
123. Therapeutic potential of blocking HIV entry into cells: Focus on membrane fusion inhibitors
124. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
125. Potent inhibition of HIV-1 replication in vitro and in vivo by a synthetic hybrid peptide inhibitor of HIV-1, SIV, and HIV-2 fusion
126. AR177 inhibits HIV-1 entry in vivo
127. A more potent CXCR4-dependent inhibitor, T140
128. CCR5 antagonists either inhibit HIV-1 infection of hu-PBL-SCID mice or select for CXCR4-using variants
129. Modulation of HIV-1 frameshift efficiency: A new target for therapeutic intervention
130. HIV regulatory proteins: Targets of triciribine?
131. Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme
132. Antisense RNA sequences targeting the 5′ leader region of human immunodeficiency virus type-1 inhibit replication at early stages of the post-transcriptional life cycle
133. Stable human immunodeficiency virus type 1 (HIV-1) resistance in transformed CD4+ monocytic cells treated with multitargeting HIV-1 antisense sequences incorporated into U1 snRNA
134. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T-lymphoblastoid cell line
135. Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys
136. Inhibition of HIV-1 in CEM cells by a potent TAR decoy
137. RNA-based gene therapy for HIV infection
138. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 phase II vaccine investigators
139. A novel hybrid synthetic peptide inhibitor of HIV-1, SIV, and HIV-2 fusion in vitro
140. Outcome after 1 year of HAART, three cycles of STI and 12 months off therapy versus natural evolution without ART in early chronic HIV-1 infection (CHI). A case-control study
141. Safety and efficacy of FP-21399 a novel fusion inhibitor - Results of a 48 week phase II study
142. Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T-cell immunity
143. A phase I dose escalation trial of PRO 542, a novel inhibitor of HIV-1 entry
144. The timing of GM-CSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-specific DNA vaccine
145. HIV-1-specific T-cell responses and spontaneous control of viremia can be detected after the first cycle of structured treatment interruptions (STI) in patients receiving HAART since primary HIV-1 infection (PHI)
146. Potent inhibition of HIV-1 replication in vivo by a novel inhibitor of HIV-1 fusion
147. Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-grading FLICE/caspase-8
148. Sensitization of T cells to CD95- mediated apoptosis by HIV-1 Tat and gp 120
149. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
150. Simian immunodeficiency virus DNA vaccine trial in macaques
151. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response